Mutual of America Capital Management LLC Has $2.31 Million Stock Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Mutual of America Capital Management LLC lessened its position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 4.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,311 shares of the company’s stock after selling 335 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Karuna Therapeutics were worth $2,314,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. First Horizon Advisors Inc. lifted its stake in shares of Karuna Therapeutics by 57.3% during the first quarter. First Horizon Advisors Inc. now owns 151 shares of the company’s stock valued at $27,000 after acquiring an additional 55 shares during the period. PNC Financial Services Group Inc. increased its holdings in Karuna Therapeutics by 87.7% in the second quarter. PNC Financial Services Group Inc. now owns 152 shares of the company’s stock valued at $33,000 after purchasing an additional 71 shares during the last quarter. Signaturefd LLC increased its holdings in Karuna Therapeutics by 266.7% in the third quarter. Signaturefd LLC now owns 275 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares during the last quarter. Lazard Asset Management LLC bought a new stake in Karuna Therapeutics in the second quarter valued at about $48,000. Finally, Almanack Investment Partners LLC. bought a new stake in Karuna Therapeutics in the third quarter valued at about $51,000.

Insider Activity at Karuna Therapeutics

In related news, insider Stephen K. Brannan sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $316.13, for a total transaction of $1,580,650.00. Following the completion of the transaction, the insider now directly owns 41,150 shares of the company’s stock, valued at $13,008,749.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.20% of the company’s stock.

Karuna Therapeutics Stock Performance

NASDAQ:KRTX opened at $329.83 on Friday. The company has a market cap of $12.58 billion, a PE ratio of -28.14 and a beta of 1.18. Karuna Therapeutics, Inc. has a 52-week low of $158.38 and a 52-week high of $329.99. The stock has a 50-day simple moving average of $324.58 and a 200 day simple moving average of $265.86.

Karuna Therapeutics (NASDAQ:KRTX) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($3.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.65) by ($0.36). Karuna Therapeutics’s revenue was down 100.0% on a year-over-year basis. During the same period last year, the company posted ($2.22) earnings per share. On average, research analysts predict that Karuna Therapeutics, Inc. will post -11.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Leerink Partnrs downgraded Karuna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, December 22nd. Morgan Stanley reiterated an “equal weight” rating and issued a $330.00 price objective (up previously from $295.00) on shares of Karuna Therapeutics in a report on Friday, December 22nd. JMP Securities reiterated a “market perform” rating on shares of Karuna Therapeutics in a report on Friday, December 22nd. Wedbush downgraded Karuna Therapeutics from an “outperform” rating to a “neutral” rating and set a $330.00 price target for the company. in a report on Friday, December 22nd. Finally, HC Wainwright restated a “neutral” rating and issued a $330.00 price target on shares of Karuna Therapeutics in a report on Thursday, March 14th. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $293.92.

Karuna Therapeutics Profile

Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease.